NTI164 not checked
Fenix Innovation Group · FEN164
FollowEvery change as it happens, and a Monday email
Trials
2 active
7 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A CBDA-dominant full-spectrum medicinal cannabis plant extract with extremely low THC.”In the company’s words, NCT07257939 on ClinicalTrials.gov
- Tested for
- Autism, Autism Spectrum Disorder, Autism Disorder, RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome
- Main trialPhase 3
- “This is a double-blind, randomised, placebo-controlled study investigating the efficacy of a full-spectrum medicinal cannabis plant extract on core and associated ASD symptoms over placebo. Participants will be randomly allocated to either NTI164 or placebo at a 1:1 ratio and blood samples will be collected and surveys completed at baseline and Week 16. This study will expand efficacy and safety data of NTI164 and provide additional mechanism of action data of NTI164 in this patient cohort.”In the company’s words, NCT07257939 on ClinicalTrials.gov
- Other names
- FEN164
Other drugs for Autism
- CM-ATCuremark · Phase 3
- CodabakalnerSpinogenix · Phase 2/3
- Xanomeline/Trospium ChlorideBristol Myers Squibb · Phase 3
- ML-004MapLight Therapeutics · Phase 2
- Terpenes-Enriched CBD-Predominant OilBazelet Nehushtan LtD. · Phase 2
- Use autologous cSVFBlack Tie Medical, Inc. · Phase 1/2
Coming up2
- 1 Oct 2028Phase 2/3 trial completes · ClinicalTrials.gov
- 1 Jul 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 1 Jul 2029 | NTI164 in Autism Spectrum Disorder | |
| Phase 2/3Not yet recruiting | 1 Oct 2028 | Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome | |
| Phase 2/3Completed | 1 Mar 2024 | Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder | |
| Phase 1/2Completed | 1 Sep 2022 | Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder. | |
| Phase 1/2Completed | 1 Dec 2025 | Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) | |
| Phase 1/2Completed | 1 Dec 2025 | Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT) | |
| Phase 1Completed | 1 Jun 2025 | NTI164 Human PK Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026